Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

August 27, 2026

Study Completion Date

August 27, 2028

Conditions
Lung AdenocarcinomaCryotherapy Effect
Interventions
DEVICE

Cryoablation

"Cryoablation will be performed by a specialized radiologist, percutaneously, ie through the skin. The operation is performed under general anesthesia, under the guidance of the scanner. The images from the scanner make it possible to precisely insert and place a needle at the level of the tumor to be treated. Intense cold will be produced by the needle and will destroy the cancer cells by freezing (temperatures of -40 °C). Freezing is localized to the tumor, the rest of the organ will not suffer from the cold.~The aftermath of the intervention causes only minimal pain and in most cases does not require pain treatment. As the operation is minimally traumatic, the risk of complications is low. Hospitalization is around twenty-four hours and usual or professional activities can be resumed very quickly."

DRUG

Pembrolizumab

Pembrolizumab will be prescribed and administered at the dose recommended by market authorization.

DRUG

Pemetrexed

Pemetrexed will be prescribed and administered at the dose recommended by market authorization.

DRUG

Carboplatin

Carboplatin will be prescribed and administered at the dose recommended by market authorization.

Trial Locations (1)

33076

RECRUITING

Institut Bergonié, Bordeaux

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Institut Bergonié

OTHER

NCT04339218 - Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma | Biotech Hunter | Biotech Hunter